49 related articles for article (PubMed ID: 19958587)
1. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
[TBL] [Abstract][Full Text] [Related]
2. Tegafur and 5-fluorouracil levels in tears and changes in tear volume in long-term users of the oral anticancer drug S-1.
Kuriki R; Hata T; Nakayama K; Ito Y; Misawa K; Ito S; Tatematsu M; Kaneda N
Nagoya J Med Sci; 2019 Aug; 81(3):415-425. PubMed ID: 31579332
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
Konno H; Tanaka T; Baba M; Kanai T; Matsumoto K; Kamiya K; Nakamura S
Jpn J Cancer Res; 1999 Apr; 90(4):448-53. PubMed ID: 10363584
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of oxaliplatin combined with S-1 (SOX) chemotherapy in a rat model of colorectal cancer with acute kidney injury: predictive renal biomarkers for dose optimisation.
Tanaka T; Kobuchi S; Ito Y; Sakaeda T
Xenobiotica; 2023; 53(10-11):613-620. PubMed ID: 37966716
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil.
Hsieh CH; Liu CY; Hsieh YJ; Tai HC; Wang LY; Tsai TH; Chen YJ
PLoS One; 2011; 6(6):e21000. PubMed ID: 21695264
[TBL] [Abstract][Full Text] [Related]
6. Circadian rhythms in CYP2A5 expression underlie the time-dependent effect of tegafur on breast cancer.
Yoshida Y; Fukuda T; Tanihara T; Nishikawa N; Iwasa S; Adachi S; Zaitsu O; Terada Y; Tsukamoto R; Shimoshikiryo H; Fukuoka K; Tsurusaki F; Hamamura K; Oyama K; Tsuruta A; Koyanagi S; Matsunaga N; Ohdo S
Biochem Biophys Res Commun; 2024 May; 708():149813. PubMed ID: 38522403
[TBL] [Abstract][Full Text] [Related]
7. Practical Consensus Guidelines for the Use of S-1 in GI Malignancies.
Parikh PM; Sahoo TP; Biswas G; Talwar V; Sp S; Panda SS; Cb A; Shetty N; Ramesh A; Ghosh J; Shetty VV; Naik R; Singh A; Gupta G; Parekh B
South Asian J Cancer; 2024 Jan; 13(1):77-82. PubMed ID: 38721104
[TBL] [Abstract][Full Text] [Related]
8. Effect of Liver Dysfunction on S-1 Therapy Induced Adverse Effects: A Retrospective Cohort Study.
Ando Y; Shibata Y; Ishihara T; Nishibe-Toyosato S; Ito K; Miyata-Hiraga N; Kawada K; Ikeda Y; Hayashi T; Imaizumi K; Yamada S
In Vivo; 2024; 38(2):767-773. PubMed ID: 38418130
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.
Sun X; Guo S
Pathol Oncol Res; 2020 Jan; 26(1):121-131. PubMed ID: 30519982
[TBL] [Abstract][Full Text] [Related]
10. Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.
Leelakanok N; Geary S; Salem A
J Pharm Sci; 2018 Feb; 107(2):513-528. PubMed ID: 29045885
[TBL] [Abstract][Full Text] [Related]
11. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
15. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
16. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
17. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
